Microsoft and our third-party vendors use cookies to store and access information such as unique IDs to deliver, maintain and improve our services and ads. If you agree, MSN and Microsoft Bing ...
Background and Aim: A number of studies have shown that hepatitis virus infections may be associated with cholangiocarcinoma (CC). However, the relationship between hepatitis B virus (HBV ...
Medical oncologist Ghassan Abou-Alfa and his clinical team work closely to ensure that chemotherapy and other treatments are well-coordinated. This provides patients with the highest level of care.
Relay Therapeutics, Elevar announce partnership for exclusive global licensing agreement for lirafugratinib: Cambridge, Massachusetts Thursday, December 5, 2024, 14:00 Hrs [IST] R ...
At Memorial Sloan Kettering, we know that even after you’ve finished bile duct cancer treatments, you may still need our help. We’re committed to supporting you in every way we can — physically, ...
A total of 20 intrahepatic cholangiocarcinoma patients were efficacy evaluable. The objective response rate (ORR) and disease control rate (DCR) were 25.0% and 80.0%, the median progression free ...
NEW YORK – Relay Therapeutics and Elevar Therapeutics on Wednesday announced an exclusive global licensing agreement for lirafugratinib (RLY-4008) in FGFR2-driven cancers.
Robust and expanding development portfolio with multiple key data readouts projected over the next 18 months Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., Nov. 12, ...